NORDIC NANOVECTOR: ABSTRACT DESCRIBING PRECLINICAL RESEARCH WITH BETALUTIN® ACCEPTED FOR PRESENTATION AT THE 57TH ASH ANNUAL MEETING

Oslo, Norway, 5 November 2015
Nordic Nanovector ASA (OSE: NANO) announces that an abstract describing preclinical research with Betalutin® (177Lu-HH1) conducted by the Company and its scientific collaborators has been accepted for poster presentation at the 57th Annual American Society of Hematology (ASH) meeting (5-8 December 2015 in Orlando, FL, USA).

The ASH annual meeting is the premier event for scientific exchange in the field of hematology, attracting more than 20,000 attendees from all over the world. Typically, more than 5,000 scientific abstracts are submitted each year, and more than 3,000 abstracts are accepted for oral and poster presentations through an extensive peer review process.

Nordic Nanovector submitted two abstracts for presentation at this year’s meeting, one of which has been accepted as noted above and below. The second abstract, describing efficacy and safety results of a Phase 1 study with Betalutin® in patients with relapsed CD37+ Non-Hodgkin Lymphoma, was not accepted for presentation. This abstract was submitted in August and contains no new material information compared with the latest poster presented at the 13th International Conference on Malignant Lymphoma in Lugano, Switzerland in June. The abstract will be published online in the 3 December 2015 supplemental volume of Blood. The Company is planning to present updated clinical data from the ongoing Phase 1/2 dose-finding study at another scientific conference in early 2016.

The accepted abstract is entitled “Treatment with 177Lu-HH1 Increases CD20 Expression in Non-Hodgkin Lymphoma Cells in Vitro and In Vivo.”

Details of the poster presentation are as follows:

Authors:   Ada H.V. Repetto-Llamazares et al
Abstract No.   3245
Session Name:   802. Chemical Biology and Experimental Therapeutics: Poster II
Date:   Sunday, 6 December 2015
Time:   6:00 PM - 8:00 PM (Eastern Standard Time)
Location:   Orange County Convention Center, Hall A
Link to abstract:  https://ash.confex.com/ash/2015/webprogram/Paper77654.html

###

For further information, please contact:

Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601

Tone Kvåle, Chief Financial Officer
Tel: +47 22 18 33 01
Cell: +47 91 51 95 76

International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson) 
nordicnanovector@citigatedr.co.uk
Tel: +44 207 282 2948/+44 207 282 2949

About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com

Tags:

About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at www.nordicnanovector.com

Subscribe